Argenx
ARGX
#404
Rank
NZ$107.58 B
Marketcap
NZ$1,730
Share price
-0.55%
Change (1 day)
36.79%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$27.62. In 2025 the company made an earnings per share (EPS) of NZ$36.82 an increase over its 2024 EPS that were of NZ$24.32.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23-26.06%
2025NZ$36.8251.44%
2024NZ$24.32-369.77%
2023NZ-$9.01-60.46%
2022NZ-$22.8063.33%
2021NZ-$13.96-40.37%
2020NZ-$23.41183.47%
2019NZ-$8.26123.09%
2018NZ-$3.7054.93%
2017NZ-$2.3914.07%
2016NZ-$2.0913.05%
2015NZ-$1.85-36.34%
2014NZ-$2.91209.04%
2013NZ-$0.94-33.99%
2012NZ-$1.43185.59%
2011NZ-$0.50